Research Triangle Park, North Carolina 27709

  • HIV Infections


To facilitate provision of atovaquone (566C80) to patients who have severe Pneumocystis carinii pneumonia (PCP) and are intolerant and/or unresponsive to trimethoprim / sulfamethoxazole ( TMX / SMX ); to monitor serious adverse events attributable to 566C80.


Inclusion Criteria Patients must have the following: - Clinical diagnosis of acute severe Pneumocystis carinii pneumonia (PCP). - Dose-limiting intolerance to TMP / SMX and parenteral pentamidine. - Willingness and ability to give informed consent. Exclusion Criteria Co-existing Condition: Excluded: - Patients with a history of intolerance to 566C80. Patients with the following prior conditions are excluded: History of serious dose-limiting adverse experience during previous 566C80 therapy, thought to be attributable to the drug. Required: - Trimethoprim / sulfamethoxazole (TMP/SMX); pentamidine.



Primary Contact:


Backup Contact:


Location Contact:

Research Triangle Park, North Carolina 27709
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: June 20, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.